Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Teva Launches Pravachol Generic; Ranbaxy Stuck At FDA

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Watson also enters into the pravastatin market with an authorized generic.

You may also be interested in...



Zoloft Erosion Outpaces Other Recent Generic Launches

In the first two weeks of availability, sertraline generic substitution captures more than 75% of scripts.

Zoloft Erosion Outpaces Other Recent Generic Launches

In the first two weeks of availability, sertraline generic substitution captures more than 75% of scripts.

Teva Foresees Sustained Growth Despite Slow Start To Fiscal 2006

Generics firm expects growth from generic Pravachol and generic Zocor exclusivity periods.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

US FDA’s Marks Willing To Accept Gene Therapies Occasionally Not Confirming Benefit

FDA Is ‘Getting More Aggressive’ In Going After Drug Efficacy Claims Outside Label

BIO’s New CEO Is Biotech Industry Veteran With Compelling Family Story, Ready To Take On The IRA

Patient-Focused Listening Sessions For Medicare-Negotiated Drugs: Key Takeaways From Round One

See All
UsernamePublicRestriction

Register

PS064065

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By